Siemens Showcases Multiple New IVD Solutions at AACC 2015
|
By LabMedica International staff writers Posted on 10 Aug 2015 |

Image: Overview of the Siemens Healthcare Diagnostics Booth 1409 at the AACC 2015, showcasing a multidisciplinary portfolio of Siemens’ latest IVD workflow solutions and assays in one location (Image courtesy of Siemens Healthcare).
Siemens showcases a multidisciplinary portfolio of its latest in vitro diagnostic (IVD) workflow solutions and assays in one location—Booth 1409 at the 2015 AACC Meeting & Clinical Lab Expo (July 26–30; Atlanta, GA, USA).
Siemens Healthcare Diagnostics division of Siemens Healthcare (Erlangen, Germany) reveals its latest IVD solutions: in addition to featuring its portfolio of multidisciplinary solutions designed for use in hospital, reference, and physician office laboratories and near patients’ bedsides, the booth highlights how Siemens’ customers are achieving their clinical and workflow goals.
“Customers need a reliable partner who can help them achieve higher levels of operational efficiency while providing quality results that lead to optimal patient care,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics, “The solutions we are showcasing at this year’s AACC can help customers successfully achieve their workflow and clinical goals, regardless of the size of their operations or testing demands.”
One such example, the ADVIA Centaur XPT Immunoassay System1 is a high-throughput analyzer that enhances workflow to meet demands for reliable, rapid immunoassay testing. Recently FDA-cleared, this analyzer is designed to provide simple, continuous operation; accurate, timely results; and powerful, seamless connectivity including to Aptio Automation, the company’s flexible, track-based automation system.
Aptio Automation’s connectivity options include the ADVIA Chemistry XPT System—Siemens’ newest high-throughput chemistry analyzer, and the Sysmex CS-5100 System2 – a high-volume hemostasis analyzer. Siemens is the only single-source provider able to connect all four key laboratory disciplines—chemistry, immunoassay, hematology, and hemostasis—to the automation track.
Also at the booth is the Sysmex CS-2100i System2—a mid-volume benchtop hemostasis analyzer. Both the Sysmex CS-2100i System and Sysmex CS 5100 System utilize simultaneous multi-wavelength detection and first-to-market PSI technology to manage unsuitable coagulation samples (e.g., improperly filled sample tubes) for high-quality results.
Another new hemostasis offering on display—one for point-of-care (POC) testing—is the Xprecia Stride Coagulation Analyzer1. Winner of the Red Dot design award, this handheld system performs prothrombin time testing (PT/INR). In hematology, Siemens now offers to small and mid-sized laboratories the ADVIA 360 Hematology System3 ADVIA 560 Hematology System3 and ADVIA 560 AL Hematology System3 – they provide state-of-the-art testing capabilities and may be used as backup systems for larger labs.
The company’s leadership is also evidenced by its latest products in urinalysis, infectious disease and molecular testing, and customer education.
The CLINITEK AUWi PRO Automated Urinalysis System4 is a walkaway solution for integrated urinalysis testing. It combines a urine chemistry analyzer (CLINITEK Novus Automated Urine Chemistry Analyzer) with a urine sediment analyzer (Sysmex UF-1000i Automated Urine Particle Analyzer).
New infectious disease assays include the ADVIA Centaur HIV Ag/Ab Combo (C-HIV) assay, which allows for sensitive and specific detection of HIV p24 antigen and antibodies and may improve detection of early acute infections. The ADVIA Centaur Syphilis assay is used as a diagnostic aid, allowing for sensitive and specific detection of antibodies to Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate).
In molecular testing, experts will be on hand to discuss the automated Siemens Tissue Preparation Solution, a reproducible and standardized process for the extraction of high-quality nucleic acid from formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissues. It is enabling technology for the next generation of molecular diagnostics, including next-generation sequencing (NGS) for infectious disease and oncology testing.
Another innovative offering making its debut at AACC is Siemens PEPconnect, part of the total Personalized Education Plan (PEP)5, the industry’s first personalized learning and performance experience for healthcare professionals and their workgroup communities. With optimized technology and increased search capabilities, PEPconnect enables to access education and real-time performance support almost anytime, anywhere, and on almost any device, including smartphones.
At AACC, Siemens also offers educational workshops on chronic kidney disease and Centers for Disease Control (CDC) recommendations for syphilis and hepatitis C testing.
Related Links:
Siemens Healthcare at AACC 2015
Siemens Healthcare at AACC 2015, featured products
American Association for Clinical Chemistry (AACC)
Siemens Healthcare Diagnostics division of Siemens Healthcare (Erlangen, Germany) reveals its latest IVD solutions: in addition to featuring its portfolio of multidisciplinary solutions designed for use in hospital, reference, and physician office laboratories and near patients’ bedsides, the booth highlights how Siemens’ customers are achieving their clinical and workflow goals.
“Customers need a reliable partner who can help them achieve higher levels of operational efficiency while providing quality results that lead to optimal patient care,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics, “The solutions we are showcasing at this year’s AACC can help customers successfully achieve their workflow and clinical goals, regardless of the size of their operations or testing demands.”
One such example, the ADVIA Centaur XPT Immunoassay System1 is a high-throughput analyzer that enhances workflow to meet demands for reliable, rapid immunoassay testing. Recently FDA-cleared, this analyzer is designed to provide simple, continuous operation; accurate, timely results; and powerful, seamless connectivity including to Aptio Automation, the company’s flexible, track-based automation system.
Aptio Automation’s connectivity options include the ADVIA Chemistry XPT System—Siemens’ newest high-throughput chemistry analyzer, and the Sysmex CS-5100 System2 – a high-volume hemostasis analyzer. Siemens is the only single-source provider able to connect all four key laboratory disciplines—chemistry, immunoassay, hematology, and hemostasis—to the automation track.
Also at the booth is the Sysmex CS-2100i System2—a mid-volume benchtop hemostasis analyzer. Both the Sysmex CS-2100i System and Sysmex CS 5100 System utilize simultaneous multi-wavelength detection and first-to-market PSI technology to manage unsuitable coagulation samples (e.g., improperly filled sample tubes) for high-quality results.
Another new hemostasis offering on display—one for point-of-care (POC) testing—is the Xprecia Stride Coagulation Analyzer1. Winner of the Red Dot design award, this handheld system performs prothrombin time testing (PT/INR). In hematology, Siemens now offers to small and mid-sized laboratories the ADVIA 360 Hematology System3 ADVIA 560 Hematology System3 and ADVIA 560 AL Hematology System3 – they provide state-of-the-art testing capabilities and may be used as backup systems for larger labs.
The company’s leadership is also evidenced by its latest products in urinalysis, infectious disease and molecular testing, and customer education.
The CLINITEK AUWi PRO Automated Urinalysis System4 is a walkaway solution for integrated urinalysis testing. It combines a urine chemistry analyzer (CLINITEK Novus Automated Urine Chemistry Analyzer) with a urine sediment analyzer (Sysmex UF-1000i Automated Urine Particle Analyzer).
New infectious disease assays include the ADVIA Centaur HIV Ag/Ab Combo (C-HIV) assay, which allows for sensitive and specific detection of HIV p24 antigen and antibodies and may improve detection of early acute infections. The ADVIA Centaur Syphilis assay is used as a diagnostic aid, allowing for sensitive and specific detection of antibodies to Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate).
In molecular testing, experts will be on hand to discuss the automated Siemens Tissue Preparation Solution, a reproducible and standardized process for the extraction of high-quality nucleic acid from formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissues. It is enabling technology for the next generation of molecular diagnostics, including next-generation sequencing (NGS) for infectious disease and oncology testing.
Another innovative offering making its debut at AACC is Siemens PEPconnect, part of the total Personalized Education Plan (PEP)5, the industry’s first personalized learning and performance experience for healthcare professionals and their workgroup communities. With optimized technology and increased search capabilities, PEPconnect enables to access education and real-time performance support almost anytime, anywhere, and on almost any device, including smartphones.
At AACC, Siemens also offers educational workshops on chronic kidney disease and Centers for Disease Control (CDC) recommendations for syphilis and hepatitis C testing.
Related Links:
Siemens Healthcare at AACC 2015
Siemens Healthcare at AACC 2015, featured products
American Association for Clinical Chemistry (AACC)
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







